$1.18
11.99% yesterday
NYSE, May 20, 10:15 pm CET
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Prime Medicine Stock price

$1.18
-0.22 15.47% 1M
-1.82 60.70% 6M
-1.75 59.76% YTD
-6.36 84.40% 1Y
-15.83 93.09% 3Y
-15.83 93.09% 5Y
-15.83 93.09% 10Y
NYSE, Closing price Tue, May 20 2025
-0.16 11.99%
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Key metrics

Market capitalization $154.27m
Enterprise Value $131.16m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 34.07
P/S ratio (TTM) P/S ratio 40.07
P/B ratio (TTM) P/B ratio 1.44
Revenue growth (TTM) Revenue growth 550.76%
Revenue (TTM) Revenue $3.85m
EBIT (operating result TTM) EBIT $-206.52m
Free Cash Flow (TTM) Free Cash Flow $-111.41m
Cash position $144.26m
EPS (TTM) EPS $-1.66
P/E forward negative
P/S forward 11.63
EV/Sales forward 9.89
Short interest 24.37%
Show more

Is Prime Medicine a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Prime Medicine Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Prime Medicine forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Prime Medicine forecast:

Buy
75%
Hold
25%

Financial data from Prime Medicine

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3.85 3.85
553% 553%
100%
- Direct Costs 6.51 6.51
44% 44%
169%
-2.67 -2.67
76% 76%
-69%
- Selling and Administrative Expenses 39 39
76% 76%
1,020%
- Research and Development Expense 158 158
2% 2%
4,106%
-200 -200
6% 6%
-5,195%
- Depreciation and Amortization 6.51 6.51
44% 44%
169%
EBIT (Operating Income) EBIT -207 -207
3% 3%
-5,364%
Net Profit -202 -202
1% 1%
-5,247%

In millions USD.

Don't miss a Thing! We will send you all news about Prime Medicine directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prime Medicine Stock News

Neutral
GlobeNewsWire
one day ago
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --
Neutral
GlobeNewsWire
one day ago
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --
Neutral
GlobeNewsWire
13 days ago
-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) --  Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
More Prime Medicine News

Company Profile

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Head office United States
CEO Keith Gottesdiener
Employees 214
Founded 2019
Website www.primemedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today